LUZU
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUZU (LUZU).
Luliconazole inhibits fungal lanosterol 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Minimal systemic absorption; absorbed fraction undergoes hepatic metabolism primarily via CYP3A4 and CYP2C19 |
| Excretion | Luliconazole is primarily eliminated via hepatic metabolism; renal excretion accounts for less than 1% of the dose; fecal excretion accounts for approximately 78-82% of the administered dose as metabolites; biliary excretion is a minor route. |
| Half-life | The terminal elimination half-life is approximately 140 hours (range 130-177 hours); this long half-life supports once-daily dosing and provides sustained drug concentrations in the skin following topical application. |
| Protein binding | >99% bound to plasma proteins, primarily albumin; the high protein binding limits systemic distribution. |
| Volume of Distribution | After topical application, the volume of distribution is not clinically meaningful due to minimal systemic absorption; following intravenous administration in animal studies, Vd is approximately 1.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Following topical application, systemic bioavailability is <0.1% due to low percutaneous absorption; oral bioavailability is not clinically relevant as the drug is not administered orally. |
| Onset of Action | For topical application: Clinical improvement is observed within 1 week of treatment initiation; mycological cure may be seen as early as 2 weeks. |
| Duration of Action | The duration of action extends beyond the treatment period due to prolonged skin retention; for tinea pedis, a 2-week treatment course results in clinical cure rates at 3-4 weeks post-treatment; for tinea cruris/corporis, a 1-week course similarly provides sustained effect. |
Apply a thin layer of luliconazole 1% cream to the affected skin once daily for 2 weeks (tinea pedis), 1 week (tinea cruris, tinea corporis).
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for any degree of renal impairment. |
| Liver impairment | No dosage adjustment required for mild to severe hepatic impairment (Child-Pugh A, B, C). |
| Pediatric use | Approved for use in patients 12 years and older with same dosing as adults. Safety and efficacy in children <12 years not established. |
| Geriatric use | No specific dose adjustments; use same dosing as younger adults based on clinical studies. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LUZU (LUZU).
| Breastfeeding | It is not known if luliconazole is excreted in human milk. No M/P ratio available. Due to low systemic absorption after topical application, risk to nursing infant is likely low. Caution should be exercised when administered to a nursing woman. |
| Teratogenic Risk | Pregnancy Category C. No adequate studies in pregnant women. In animal studies, topical administration of luliconazole during organogenesis resulted in embryofetal toxicity at systemic exposures less than the maximum recommended human dose. Risk cannot be ruled out. First trimester: Use only if potential benefit justifies potential risk. Second and third trimesters: Limited data; avoid if possible. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to luliconazole or any component of the formulation
| Precautions | For external use only; avoid contact with eyes, mouth, or vagina; discontinue if hypersensitivity or irritation occurs; use during pregnancy only if clearly needed; not evaluated for treatment of onychomycosis or scalp infections |
Loading safety data…
| Fetal Monitoring | No specific maternal or fetal monitoring required beyond standard obstetric care. Observe for local irritation or allergic reactions at application site. |
| Fertility Effects | No human studies on fertility. In animal studies, no impairment of fertility was observed in male or female rats at oral doses up to 50 mg/kg/day. |